Therefore, in the present study, we evaluated the efficacy of two novel C‐terminal inhibitors in targeting chemo‐resistance pathways in melanoma cells resistant to BRAF‐ and MEK‐inhibitors. This evidence concerns the gene MAP2K7 and melanoma.